Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome
- PMID: 15822040
- DOI: 10.1016/s1542-3565(04)00726-8
Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome
Abstract
Background & aims: 5-hydroxytryptamine-3 (5-HT 3 ) receptor antagonists improve symptoms in patients with diarrhea-predominant irritable bowel syndrome (D-IBS), 5-HT 4 agonists help those with constipation-predominant IBS (C-IBS). These data suggest excess or deficiency in 5-HT in D-IBS or C-IBS, respectively. Mucosal 5-HT-containing enterochromaffin cells (EC) are increased in postinfectious IBS (PI-IBS). Our aim was to define the postprandial release of 5-HT in PI-IBS and C-IBS patients and to relate this to mucosal 5-HT turnover.
Methods: Fifteen PI-IBS patients with diarrhea-predominant symptoms, 15 C-IBS patients, and 15 healthy controls underwent serial (platelet-poor) plasma 5-HT measurement for 3 hours after a standard 520-kcal meal. Rectal biopsy specimens were assayed for 5-HT and its metabolite 5-hydroxindoleacetic acid (5-HIAA). Colonic transit was measured using radio-opaque markers.
Results: Colonic transit was prolonged in C-IBS patients (mean +/- SEM) (49.4 +/- 3.8 h) compared with PI-IBS (26.7 +/- 4.5) and control patients (34.1 +/- 4.5) ( P < .02). Release of 5-HT assessed by area under the curve (AUC) of platelet-poor plasma 5-HT from 0 to 180 minutes postprandially was significantly lower in C-IBS patients (2593 +/- 309 mmol/L . min) compared with P-IBS (5623 +/- 721) and control patients (4822 +/- 598) ( P < .001). PI-IBS patients showed significantly higher peak postprandial plasma 5-HT values (median, range) (71.7, 43.4-125.3) ng/L compared with C-IBS patients (31.2, 15.2-40.5) and control patients (43.6, 26.7-50.1) ( P < .01). Mucosal 5-HT turnover as assessed by mucosal 5-HIAA/5-HT ratio was decreased in both C-IBS and PI-IBS patients, .14 (.01-.6) and .21 (.02-2.5), respectively, compared with control patients 1.12 (.17-3.1) ( P < .002).
Conclusions: C-IBS patients show impaired postprandial 5-HT release whereas PI-IBS patients have higher peak levels, abnormalities that may be related to their different symptoms.
Similar articles
-
Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome.Gastroenterology. 2006 Jan;130(1):34-43. doi: 10.1053/j.gastro.2005.09.031. Gastroenterology. 2006. PMID: 16401466
-
Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study.Gut. 1998 Jan;42(1):42-6. doi: 10.1136/gut.42.1.42. Gut. 1998. PMID: 9505884 Free PMC article.
-
Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.Am J Gastroenterol. 2011 Jul;106(7):1290-8. doi: 10.1038/ajg.2011.86. Epub 2011 Mar 22. Am J Gastroenterol. 2011. PMID: 21427712
-
[Role of serotonin in the pathophysiology of the irritable bowel syndrome].Wiad Lek. 2007;60(7-8):371-6. Wiad Lek. 2007. PMID: 18175558 Review. Polish.
-
Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease.Neurogastroenterol Motil. 2007 Aug;19 Suppl 2:25-31. doi: 10.1111/j.1365-2982.2007.00965.x. Neurogastroenterol Motil. 2007. PMID: 17620085 Review.
Cited by
-
IBS and IBD - separate entities or on a spectrum?Nat Rev Gastroenterol Hepatol. 2016 Sep 26;13(10):613-21. doi: 10.1038/nrgastro.2016.141. Nat Rev Gastroenterol Hepatol. 2016. PMID: 27667579 Review.
-
[Research progress of metabolomics in children with irritable bowel syndrome].Zhongguo Dang Dai Er Ke Za Zhi. 2024 Sept 15;26(9):989-994. doi: 10.7499/j.issn.1008-8830.2404130. Zhongguo Dang Dai Er Ke Za Zhi. 2024. PMID: 39267517 Free PMC article. Review. Chinese.
-
Effects of vitamin D3 supplementation on clinical symptoms, quality of life, serum serotonin (5-hydroxytryptamine), 5-hydroxy-indole acetic acid, and ratio of 5-HIAA/5-HT in patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial.EXCLI J. 2020 May 19;19:652-667. doi: 10.17179/excli2020-2247. eCollection 2020. EXCLI J. 2020. PMID: 33013260 Free PMC article.
-
Diet in irritable bowel syndrome.Nutr J. 2015 Apr 14;14:36. doi: 10.1186/s12937-015-0022-3. Nutr J. 2015. PMID: 25880820 Free PMC article. Review.
-
Irritable bowel syndrome: bacteria and inflammation--clinical relevance now.Curr Treat Options Gastroenterol. 2007 Aug;10(4):312-21. doi: 10.1007/s11938-007-0074-3. Curr Treat Options Gastroenterol. 2007. PMID: 17761124
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous